Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of AAV-based optogenetic therapy for the treatment of patients with advanced retinal disease

Next Previous
Trial Profile

A clinical study of AAV-based optogenetic therapy for the treatment of patients with advanced retinal disease

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adeno associated virus gene delivery systems (Primary)
  • Indications Blindness; Retinal disorders
  • Focus Adverse reactions

Most Recent Events

  • 14 May 2019 New trial record
  • 03 May 2019 According to an Applied Genetic Technologies Corporation media release, Bionic Sight expects clearance of the IND and expects to initiate this study in the second half of 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top